Market's view on Surgical Innovations
Published on April 2024
- Healthinvest has increased their holding to 7%.
- Ruffer LLP sold 3,250,000 shares, reducing their stake to less than 5%.
- Observations note that former board members stepping down might lead to positive changes with new board additions.
- A forecast suggests a net cash position of around £1M and a positive operating profit by year-end, with a revenue increase of 8% year-on-year and stable or reduced costs.
- Significant growth opportunities are highlighted in India and Japan, with revenue expected to double within five years.
- There are concerns about the adequacy of EBITDA and the disposition of profits, questioning the financing of capital expenditures.
- Speculation about an impending fundraising due to the company’s financial position.
- Assertions that a sell-off in shares was unwarranted given a £0.5M reduction in costs and new contracts.
- A bleak view suggests the market valuation indicates the company is nearing insolvency.
- Discussion on the potential impact of CMR Surgical’s sales aiding the recovery of Surgical Innovations, focusing on the development and utilization of new surgical equipment in a large number of procedures.
- Concerns are raised about delayed financial results and continuing share price declines.